Download StudyGeneral

Study Overview

Evaluation of India Deworming Programme (National Deworming Day), 2018-2020
Study ID:
Initial Registration Date:
Last Update Date:
Study Status:
The proposed evaluation aims to support the Government of India (GoI) and Evidence Action (EA) in strengthening the existing deworming programme. Under the implementation grant, EA is providing technical assistance to the Governments of Uttar Pradesh, Bihar, Jharkhand, Chhattisgarh, Telangana, and Tripura. The vision is to provide Children’s Investment Fund Foundation and Evidence Action with accurate mass drug administration (MDA) coverage, assess implementation of the ongoing programme, understand challenges in implementing the NDD, and propose innovative solutions. We will undertake a coverage evaluation survey of the India Deworming Programme (National Deworming Day (NDD)) among children and adolescents aged 1-19 years in four states.
Health, Nutrition, and Population
Additional Keywords:
Coverage Evaluation, Deworming, MDA
Secondary ID Number(s):

Principal Investigator(s)

Name of First PI:
Ashutosh Mishra
Research Triangle Institute (RTI) International India
Name of Second PI:

Study Sponsor

Children’s Investment Fund Foundation
Study Sponsor Location:
United Kingdom
Funding Proposal:

Intervention Overview

We will be evaluating the GoI's national deworming day by undertaking a coverage evaluation survey of MDA among children and adolescents aged 1-19 years in the states of Chhattisgarh, Andhra Pradesh, Himachal Pradesh, and Telangana. EA works with national and state governments to strengthen and scale-up the preschool and school-based deworming program to target all children aged 1-19 years in 11 Indian states. Their primary objective is to deworm all preschool and school-aged children between the ages of 1 to 19 at preschools, and schools including government, government-aided and private schools on a single- fixed day approach (10 February and 10 August each year).
Theory of Change:
Multiple Treatment Arms Evaluated?

Intervention Timing

Intervention or Program Started at time of Registration?
Start Date:
End Date:
Evaluation Method

Evaluation Method Overview

Primary (or First) Evaluation Method:
Other (specify)
Other (not Listed) Method:
We do not intend to assess causal impact of the intervention.This is a coverage evaluation survey to understand the MDA coverage.
Additional Evaluation Method (If Any):
Other (not Listed) Method:

Method Details

Details of Evaluation Approach:
A mixed-methods approach using three different instruments: household coverage survey, qualitative interviews with key informants, and cost analysis. Conduct both a baseline and an endline survey in 4 states, two with EA intervention and two without (i.e. control). Coverage Evaluation: The design for this state level population-based survey will be based on the WHO guidance on how to conduct district level coverage surveys - “Coverage Evaluation Surveys for Preventative Chemotherapy: Field guide for Implementation”. We will modify the design to allow for robust state level representation of coverage. The proposed design will allow for some disaggregation within each state for example by Lymphatic Filariasis (LF) endemicity, STH prevalence, or urban/rural areas. Background characteristics of respondents such as gender, age, and school attendance will also be collected, but the survey will not be powered to measure coverage among these groups.
Outcomes (Endpoints):
Some of the outcome indicators for coverage evaluation are as follows: 1. Proportion of children aged 1-19 RECEIVING albendazole for STH, by state, age, and sex 2. Proportion of children aged 1-19 SWALLOWING albendazole for STH, by state, age, and sex 3. Proportion of parents aware of deworming program 4. Proportion of children who report that they will swallow the tablet next time
Unit of Analysis:
The proposed community survey (undertaken at the household level) will provide state level estimates.
We want to test the hypothesis that EA supported states (here, Chattisgarh and Telangana) will have a better drug coverage (in particular, proportion of children who swallow the drug) compared to non-EA supported states (Andhra Pradesh and Himachal Pradesh).
Unit of Intervention or Assignment:
Individuals (children and adolescents aged 1-19 years)
Number of Clusters in Sample:
100 clusters per state
Number of Individuals in Sample:
2000 households per state
Size of Treatment, Control, or Comparison Subsamples:
4000 households in intervention arm and 4000 households in comparison arm

Supplementary Files

Analysis Plan:
Other Documents:

Outcomes Data

We will conduct face-to-face surveys of households with children and adolescents aged 1-19 years.
Data Already Collected?
Survey Name:
Data Previously Used?
Data Access:
Data Obtained by the Study Researchers?
Data Approval Process:
Approval Status:

Treatment Assignment Data

Participation or Assignment Information:
Data Obtained by the Study Researchers?
Data Previously Used?
Data Access:
Data Obtained by the Study Researchers?
Data Approval Process:
Approval Status:

Data Analysis

Data Analysis Status:

Study Materials

Upload Study Materials:

Registration Category

Registration Category:
Prospective, Category 1: Data for measuring impacts have not been collected

Completion Overview

Intervention Completion Date:
Data Collection Completion Date:
Unit of Analysis:
Clusters in Final Sample:
Total Observations in Final Sample:
Size of Treatment, Control, or Comparison Subsamples:


Preliminary Report:
Preliminary Report URL:
Summary of Findings:
Paper Summary:
Paper Citation:

Data Availability

Data Availability (Primary Data):
Date of Data Availability:
Data URL or Contact:
Access procedure:

Other Materials

Survey Instrument Links or Contact:
Program Files:
Program Files Links or Contact:
External Link:
External Link Description:
Description of Changes:

Study Stopped